Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Global state: Relapse ‐ long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
1 finding from 1 review
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review
Relapse · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review